-
1
-
-
34548042964
-
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombo-cythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel
-
Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombo-cythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110:1092-7.
-
(2007)
Blood
, vol.110
, pp. 1092-1097
-
-
Tefferi, A.1
Thiele, J.2
Orazi, A.3
-
2
-
-
8344229870
-
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
-
Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117:755-61.
-
(2004)
Am J Med
, vol.117
, pp. 755-761
-
-
Passamonti, F.1
Rumi, E.2
Pungolino, E.3
-
3
-
-
33646406275
-
Relation between JAK2 (V617F) mutation status granulocyte activation and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
-
Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107:3676-82.
-
(2006)
Blood
, vol.107
, pp. 3676-3682
-
-
Passamonti, F.1
Rumi, E.2
Pietra, D.3
-
4
-
-
33750534561
-
MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients
-
Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108:3472-6.
-
(2006)
Blood
, vol.108
, pp. 3472-3476
-
-
Pardanani, A.D.1
Levine, R.L.2
Lasho, T.3
-
5
-
-
77950994977
-
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms
-
Thoennissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 2010; 115:2882-90.
-
(2010)
Blood
, vol.115
, pp. 2882-2890
-
-
Thoennissen, N.H.1
Krug, U.O.2
Lee, D.H.3
-
6
-
-
41849140470
-
20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: Predictors at diagnosis
-
Tefferi A, Gangat N, Wolanskyj AP, et al. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol 2008; 80:386-90.
-
(2008)
Eur J Haematol
, vol.80
, pp. 386-390
-
-
Tefferi, A.1
Gangat, N.2
Wolanskyj, A.P.3
-
7
-
-
63849328927
-
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
-
Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113:2895-901.
-
(2009)
Blood
, vol.113
, pp. 2895-2901
-
-
Cervantes, F.1
Dupriez, B.2
Pereira, A.3
-
8
-
-
43949103121
-
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
-
Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008; 22:905-14.
-
(2008)
Leukemia
, vol.22
, pp. 905-914
-
-
Cervantes, F.1
Passamonti, F.2
Barosi, G.3
-
9
-
-
33947262701
-
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment standard risk factors and Jak2 mutation status
-
Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109:2310-3.
-
(2007)
Blood
, vol.109
, pp. 2310-2313
-
-
Carobbio, A.1
Finazzi, G.2
Guerini, V.3
-
10
-
-
45749098579
-
Leukocytosis and risk stratification assessment in essential thrombocythemia
-
Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26:2732-6.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2732-2736
-
-
Carobbio, A.1
Antonioli, E.2
Guglielmelli, P.3
-
11
-
-
54049086618
-
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia
-
Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008; 112: 3135-7.
-
(2008)
Blood
, vol.112
, pp. 3135-3137
-
-
Carobbio, A.1
Finazzi, G.2
Antonioli, E.3
-
12
-
-
33947208087
-
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
-
Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109:2446-52.
-
(2007)
Blood
, vol.109
, pp. 2446-2452
-
-
Landolfi, R.1
Di Gennaro, L.2
Barbui, T.3
-
13
-
-
32144461605
-
Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
-
Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81:159-66.
-
(2006)
Mayo Clin Proc
, vol.81
, pp. 159-166
-
-
Wolanskyj, A.P.1
Schwager, S.M.2
McClure, R.F.3
-
14
-
-
73149090129
-
Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera
-
Gangat N, Wolanskyj AP, Schwager SM, et al. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 2009;115:5740-5.
-
(2009)
Cancer
, vol.115
, pp. 5740-5745
-
-
Gangat, N.1
Wolanskyj, A.P.2
Schwager, S.M.3
-
15
-
-
55549099571
-
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: A study of 605 patients
-
Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008; 93:1645-51.
-
(2008)
Haematologica
, vol.93
, pp. 1645-1651
-
-
Passamonti, F.1
Rumi, E.2
Arcaini, L.3
-
16
-
-
64549127701
-
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: Safety of cytoreductive therapy
-
Palandri F, Catani L, Testoni N, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol 2009; 84:215-20.
-
(2009)
Am J Hematol
, vol.84
, pp. 215-220
-
-
Palandri, F.1
Catani, L.2
Testoni, N.3
-
17
-
-
69249217916
-
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia
-
Passamonti F, Rumi E, Pascutto C, et al. Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. J Thromb Haemost 2009; 7:1587-9.
-
(2009)
J Thromb Haemost
, vol.7
, pp. 1587-1589
-
-
Passamonti, F.1
Rumi, E.2
Pascutto, C.3
-
18
-
-
0034672149
-
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera
-
Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96:4261-6.
-
(2000)
Blood
, vol.96
, pp. 4261-4266
-
-
Falanga, A.1
Marchetti, M.2
Evangelista, V.3
-
19
-
-
34447132275
-
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
-
Gangat N, Strand J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007; 138:354-8.
-
(2007)
Br J Haematol
, vol.138
, pp. 354-358
-
-
Gangat, N.1
Strand, J.2
Li, C.Y.3
-
20
-
-
34247365425
-
The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia
-
Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 2007; 109:4105.
-
(2007)
Blood
, vol.109
, pp. 4105
-
-
Tefferi, A.1
Gangat, N.2
Wolanskyj, A.3
-
21
-
-
77950945887
-
Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: A population-based study of 311 patients
-
Girodon F, Dutrillaux F, Broseus J, et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia 2010; 24:900-3.
-
(2010)
Leukemia
, vol.24
, pp. 900-903
-
-
Girodon, F.1
Dutrillaux, F.2
Broseus, J.3
-
22
-
-
55049131023
-
Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia
-
Dahabreh IJ, Zoi K, Giannouli S, et al. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009; 33:67-73.
-
(2009)
Leuk Res
, vol.33
, pp. 67-73
-
-
Dahabreh, I.J.1
Zoi, K.2
Giannouli, S.3
-
23
-
-
68549116852
-
Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
-
Lussana F, Caberlon S, Pagani C, et al. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res 2009; 124:409-17.
-
(2009)
Thromb Res
, vol.124
, pp. 409-417
-
-
Lussana, F.1
Caberlon, S.2
Pagani, C.3
-
24
-
-
34547953018
-
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
-
Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110:840-6.
-
(2007)
Blood
, vol.110
, pp. 840-846
-
-
Vannucchi, A.M.1
Antonioli, E.2
Guglielmelli, P.3
-
25
-
-
77956439565
-
A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
-
Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24:1574-9.
-
(2010)
Leukemia
, vol.24
, pp. 1574-1579
-
-
Passamonti, F.1
Rumi, E.2
Pietra, D.3
-
26
-
-
77951759127
-
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease
-
Akada H, Yan D, Zou H, et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010; 115:3589-97.
-
(2010)
Blood
, vol.115
, pp. 3589-3597
-
-
Akada, H.1
Yan, D.2
Zou, H.3
-
27
-
-
50949127379
-
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
-
Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008; 112:844-7.
-
(2008)
Blood
, vol.112
, pp. 844-847
-
-
Vannucchi, A.M.1
Antonioli, E.2
Guglielmelli, P.3
-
28
-
-
47249092413
-
MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort
-
Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112:141-9.
-
(2008)
Blood
, vol.112
, pp. 141-149
-
-
Beer, P.A.1
Campbell, P.J.2
Scott, L.M.3
-
29
-
-
67349124376
-
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
-
Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23:905-11.
-
(2009)
Leukemia
, vol.23
, pp. 905-911
-
-
Tefferi, A.1
Pardanani, A.2
Lim, K.H.3
-
30
-
-
67649933816
-
Reticulin accumulation in essential thrombocythemia: Prognostic significance and relationship to therapy
-
Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009; 27:2991-9.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2991-2999
-
-
Campbell, P.J.1
Bareford, D.2
Erber, W.N.3
-
31
-
-
77950352432
-
A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
-
Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115:1703-8.
-
(2010)
Blood
, vol.115
, pp. 1703-1708
-
-
Passamonti, F.1
Cervantes, F.2
Vannucchi, A.M.3
-
32
-
-
77957955039
-
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis
-
Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010; 116:2857-8.
-
(2010)
Blood
, vol.116
, pp. 2857-2858
-
-
Passamonti, F.1
Cervantes, F.2
Vannucchi, A.M.3
-
33
-
-
0029767865
-
Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system
-
Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88:1013-8.
-
(1996)
Blood
, vol.88
, pp. 1013-1018
-
-
Dupriez, B.1
Morel, P.2
Demory, J.L.3
-
34
-
-
0030748326
-
Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases
-
Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997; 98:96-102.
-
(1997)
Br J Haematol
, vol.98
, pp. 96-102
-
-
Reilly, J.T.1
Snowden, J.A.2
Spearing, R.L.3
-
35
-
-
77953923573
-
Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: A study of 172 patients
-
Morel P, Duhamel A, Hivert B, et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood 2010; 115:4350-5.
-
(2010)
Blood
, vol.115
, pp. 4350-4355
-
-
Morel, P.1
Duhamel, A.2
Hivert, B.3
-
36
-
-
77449126735
-
International Prognostic Scoring System: Independent cytogenetic risk categorization in primary myelofibrosis
-
Hussein K, Pardanani AD, Van Dyke DL, et al. International Prognostic Scoring System: independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010; 115:496-9.
-
(2010)
Blood
, vol.115
, pp. 496-499
-
-
Hussein, K.1
Pardanani, A.D.2
Van Dyke, D.L.3
-
37
-
-
66149113655
-
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course
-
Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009; 113:4171-8.
-
(2009)
Blood
, vol.113
, pp. 4171-4178
-
-
Tam, C.S.1
Abruzzo, L.V.2
Lin, K.I.3
-
38
-
-
77951015383
-
Validation of cytogenetic-based risk stratification in primary myelofibrosis
-
Rumi E, Passamonti F, Bernasconi P, et al. Validation of cytogenetic-based risk stratification in primary myelofibrosis. Blood 2010; 115:2719-20.
-
(2010)
Blood
, vol.115
, pp. 2719-2720
-
-
Rumi, E.1
Passamonti, F.2
Bernasconi, P.3
-
39
-
-
37049039725
-
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
-
Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110:4030-6.
-
(2007)
Blood
, vol.110
, pp. 4030-4036
-
-
Barosi, G.1
Bergamaschi, G.2
Marchetti, M.3
-
40
-
-
42449124578
-
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
-
Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-61.
-
(2008)
Leukemia
, vol.22
, pp. 756-761
-
-
Tefferi, A.1
Lasho, T.L.2
Huang, J.3
-
41
-
-
70349580685
-
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
-
Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009; 114:1477-83.
-
(2009)
Blood
, vol.114
, pp. 1477-1483
-
-
Guglielmelli, P.1
Barosi, G.2
Specchia, G.3
-
42
-
-
58149240151
-
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis
-
Guglielmelli P, Barosi G, Pieri L, et al. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica 2009; 94:144-6.
-
(2009)
Haematologica
, vol.94
, pp. 144-146
-
-
Guglielmelli, P.1
Barosi, G.2
Pieri, L.3
-
43
-
-
77956302639
-
Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibro-sis
-
Alchalby H, Badbaran A, Zabelina T, et al. Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibro-sis. Blood 2010; 116:3572-81.
-
(2010)
Blood
, vol.116
, pp. 3572-3581
-
-
Alchalby, H.1
Badbaran, A.2
Zabelina, T.3
-
44
-
-
74049158614
-
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis: Prognostic relevance is independent of IPSS or karyotype
-
Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis: prognostic relevance is independent of IPSS or karyotype. Am J Hematoly 2010; 85:14-7.
-
(2010)
Am J Hematoly
, vol.85
, pp. 14-17
-
-
Tefferi, A.1
Siragusa, S.2
Hussein, K.3
-
45
-
-
77956335991
-
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence
-
Passamonti F, Rumi E, Elena C, et al. Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br J Haematol 2010; 150: 719-21.
-
(2010)
Br J Haematol
, vol.150
, pp. 719-721
-
-
Passamonti, F.1
Rumi, E.2
Elena, C.3
|